Prime Medicine Inc. Common Stock
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $12.59
- Today's High:
- $13.2
- Open Price:
- $12.67
- 52W Low:
- $11.07
- 52W High:
- $21.73
- Prev. Close:
- $12.71
- Volume:
- 389677
Company Statistics
- Market Cap.:
- $1.24 billion
- Book Value:
- 2.635
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $-86725000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -36.81%
- Return on Equity TTM:
- -68.24%
Company Profile
Prime Medicine Inc. Common Stock had its IPO on 2022-10-20 under the ticker symbol PRME.
The company operates in the Healthcare sector and Biotechnology industry. Prime Medicine Inc. Common Stock has a staff strength of 175 employees.
Stock update
Shares of Prime Medicine Inc. Common Stock opened at $12.67 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $12.59 - $13.2, and closed at $12.95.
This is a +1.89% increase from the previous day's closing price.
A total volume of 389,677 shares were traded at the close of the day’s session.
In the last one week, shares of Prime Medicine Inc. Common Stock have increased by +1.33%.
Prime Medicine Inc. Common Stock's Key Ratios
Prime Medicine Inc. Common Stock has a market cap of $1.24 billion, indicating a price to book ratio of 0 and a price to sales ratio of 0.
In the last 12-months Prime Medicine Inc. Common Stock’s revenue was $0 with a gross profit of $-86725000 and an EBITDA of $-151960000. The EBITDA ratio measures Prime Medicine Inc. Common Stock's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Prime Medicine Inc. Common Stock’s operating margin was 0% while its return on assets stood at -36.81% with a return of equity of -68.24%.
In Q2, Prime Medicine Inc. Common Stock’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Prime Medicine Inc. Common Stock’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.57 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Prime Medicine Inc. Common Stock’s profitability.
Prime Medicine Inc. Common Stock stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -14.1918. Its price to sales ratio in the trailing 12-months stood at 0.
Prime Medicine Inc. Common Stock stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $280.87 million
- Total Liabilities
- $28.72 million
- Operating Cash Flow
- $27.86 million
- Capital Expenditure
- $1.98 million
- Dividend Payout Ratio
- 0%
Prime Medicine Inc. Common Stock ended 2024 with $280.87 million in total assets and $0 in total liabilities. Its intangible assets were valued at $280.87 million while shareholder equity stood at $240.10 million.
Prime Medicine Inc. Common Stock ended 2024 with $108000.00 in deferred long-term liabilities, $28.72 million in other current liabilities, 2000.00 in common stock, $-374979000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $120.58 million and cash and short-term investments were $207.62 million. The company’s total short-term debt was $13,509,000 while long-term debt stood at $0.
Prime Medicine Inc. Common Stock’s total current assets stands at $207.62 million while long-term investments were $0 and short-term investments were $87.04 million. Its net receivables were $1.82 million compared to accounts payable of $5.49 million and inventory worth $0.
In 2024, Prime Medicine Inc. Common Stock's operating cash flow was $27.86 million while its capital expenditure stood at $1.98 million.
Comparatively, Prime Medicine Inc. Common Stock paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $12.95
- 52-Week High
- $21.73
- 52-Week Low
- $11.07
- Analyst Target Price
- $22.33
Prime Medicine Inc. Common Stock stock is currently trading at $12.95 per share. It touched a 52-week high of $21.73 and a 52-week low of $21.73. Analysts tracking the stock have a 12-month average target price of $22.33.
Its 50-day moving average was $13.47 and 200-day moving average was $15.02 The short ratio stood at 18.54 indicating a short percent outstanding of 0%.
Around 3189.9% of the company’s stock are held by insiders while 5366.7% are held by institutions.
Frequently Asked Questions About Prime Medicine Inc. Common Stock
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.